• Axsome Therapeutics adopted an Executive Severance and Change in Control Plan effective June 5, 2026, replacing prior severance arrangements.
• Outside a change-in-control period, involuntary terminations trigger salary-based severance of 18 months for Tier 1, 12 months for Tier 2, 6 months for Tier 3.
• During a change-in-control period, severance rises to 24 months, 18 months, 9 months, paid as a lump sum with a prorated target annual incentive component.
• Change-in-control terminations also accelerate vesting: 100% of unvested time-based equity awards, performance awards at 100% of target.
• COBRA support is included, with monthly premium coverage outside change-in-control, lump-sum premium differentials for 24 months, 18 months, 9 months in-control.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Axsome Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-264047), on June 09, 2026, and is solely responsible for the information contained therein.